Unknown

Dataset Information

0

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.


ABSTRACT: We previously showed that the proteasome inhibitor carfilzomib and the histone deacetylase inhibitor (HDACI) vorinostat cooperated to induce cell apoptosis in one T-cell leukemia cell line in vitro, implying the possibility of the combination treatment of carfilzomib and vorinostat as a potential therapeutic strategy in human T-cell leukemia/lymphoma. Here we report that combination treatment of carfilzomib and vorinostat enhanced cell apoptosis and induced a marked increase in G2-M arrest, reactive oxygen species (ROS) generation, and activated the members of mitogen-activated protein kinases (MAPK) family, including the stress-activated kinases JNK, p38MAPK, and ERK1/2. Carfilzomib/vorinostat-mediated apoptosis was blocked by the ROS scavenger N-acetylcysteine (NAC). The JNK inhibitor SP600125 and the p38MAPK inhibitor SB203580 but not the MEK1/2 inhibitor U0126 significantly attenuated carfilzomib/vorinostat-induced apoptosis, suggesting that p38MAPK and JNK activation contribute to carfilzomib and vorinostat-induced apoptosis. This was further confirmed via short hairpin (shRNA) RNA knockdown of p38MAPK and JNK. Interestingly, the ROS scavenger NAC attenuated carfilzomib/vorinostat-mediated activation of p38MAPK and JNK. However, p38MAPK shRNA but not JNK shRNA diminished carfilzomib/vorinostat-mediated ROS generation. In contrast, overexpression of p38MAPK significantly increased carfilzomib/vorinostat-mediated ROS generation, suggesting that an amplification loop exists between ROS and p38MAPK pathway. Combination treatment of carfilzomib and vorinostat enhanced their individual antitumor activity in both a human xenograft model as well as human primary T-cell leukemia/lymphoma cells. These data suggest the potential clinical benefit and underlying molecular mechanism of combining carfilzomib with vorinostat in the treatment of human T-cell leukemia/lymphoma.

SUBMITTER: Gao M 

PROVIDER: S-EPMC5045381 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.

Gao Minjie M   Chen Gege G   Wang Houcai H   Xie Bingqian B   Hu Liangning L   Kong Yuanyuan Y   Yang Guang G   Tao Yi Y   Han Ying Y   Wu Xiaosong X   Zhang Yiwen Y   Dai Bojie B   Shi Jumei J  

Oncotarget 20160501 20


We previously showed that the proteasome inhibitor carfilzomib and the histone deacetylase inhibitor (HDACI) vorinostat cooperated to induce cell apoptosis in one T-cell leukemia cell line in vitro, implying the possibility of the combination treatment of carfilzomib and vorinostat as a potential therapeutic strategy in human T-cell leukemia/lymphoma. Here we report that combination treatment of carfilzomib and vorinostat enhanced cell apoptosis and induced a marked increase in G2-M arrest, reac  ...[more]

Similar Datasets

| S-EPMC9680537 | biostudies-literature
| S-EPMC6052569 | biostudies-literature
| S-EPMC11335859 | biostudies-literature
| S-EPMC7904719 | biostudies-literature
| S-EPMC8986610 | biostudies-literature
| S-EPMC11673799 | biostudies-literature
| S-EPMC3145731 | biostudies-literature
| S-EPMC5347785 | biostudies-literature
| S-EPMC5393923 | biostudies-literature
| S-EPMC8509036 | biostudies-literature